Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Progress Toward Poliovirus Containment Implementation - Worldwide, 2018-2019

Daphne B Moffett et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Among the three wild poliovirus (WPV) types, type 2 (WPV2) was declared eradicated globally by the Global Commission for the Certification of Poliomyelitis Eradication (GCC) in 2015. Subsequently, in 2016, a global withdrawal of Sabin type 2 oral poliovirus vaccine (OPV2) from routine use, through a synchronized switch from the trivalent formulation of oral poliovirus vaccine (tOPV, containing vaccine virus types 1, 2, and 3) to the bivalent form (bOPV, containing types 1 and 3), was implemented. WPV type 3 (WPV3), last detected in 2012 (1), will possibly be declared eradicated in late 2019.* To ensure that polioviruses are not reintroduced to the human population after eradication, World Health Organization (WHO) Member States committed in 2015 to containing all polioviruses in poliovirus-essential facilities (PEFs) that are certified to meet stringent containment criteria; implementation of containment activities began that year for facilities retaining type 2 polioviruses (PV2), including type 2 oral poliovirus vaccine (OPV) materials (2). As of August 1, 2019, 26 countries have nominated 74 PEFs to retain PV2 materials. Twenty-five of these countries have established national authorities for containment (NACs), which are institutions nominated by ministries of health or equivalent bodies to be responsible for poliovirus containment certification. All designated PEFs are required to be enrolled in the certification process by December 31, 2019 (3). When GCC certifies WPV3 eradication, WPV3 and vaccine-derived poliovirus (VDPV) type 3 materials will also be required to be contained, leading to a temporary increase in the number of designated PEFs. When safer alternatives to wild and OPV/Sabin strains that do not require containment conditions are available for diagnostic and serologic testing, the number of PEFs will decrease. Facilities continuing to work with polioviruses after global eradication must minimize the risk for reintroduction into communities by adopting effective biorisk management practices.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Planned major activities of the Polio Endgame Strategy — worldwide, 2019–2023 Abbreviations: CCS = Containment Certification Scheme; GAPIII = Third Global Action Plan to minimize poliovirus facility–associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral poliovirus vaccine use; GCC-CWG = Global Commission for the Certification of Poliomyelitis Eradication Containment Working Group; NAC = national authority for containment; PEF = poliovirus-essential facility; WHO = World Health Organization; WPV = wild poliovirus.

Similar articles

Cited by

  • Polio eradication in a chronic conflict setting lessons from the Republic of South Sudan, 2010-2020.
    Maleghemi S, Tegegne AA, Ferede M, Bassey BE, Akpan GU, Bello IM, Ticha JM, Anyuon A, Waya JL, Okiror SO, Ndoutabe M, Berta KK, Ndenzako F, Mkanda P, Olu OO. Maleghemi S, et al. Pan Afr Med J. 2022 Jun 9;42(Suppl 1):3. doi: 10.11604/pamj.supp.2022.42.1.32922. eCollection 2022. Pan Afr Med J. 2022. PMID: 36158939 Free PMC article.
  • Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Mbaeyi C, Moran T, Wadood Z, Ather F, Sykes E, Nikulin J, Al Safadi M, Stehling-Ariza T, Zomahoun L, Ismaili A, Abourshaid N, Asghar H, Korukluoglu G, Duizer E, Ehrhardt D, Burns CC, Sharaf M. Mbaeyi C, et al. Vaccine. 2021 Jun 23;39(28):3717-3723. doi: 10.1016/j.vaccine.2021.05.045. Epub 2021 May 27. Vaccine. 2021. PMID: 34053791 Free PMC article.
  • Progress Toward Poliovirus Containment Implementation - Worldwide, 2019-2020.
    Moffett DB, Llewellyn A, Singh H, Saxentoff E, Partridge J, Boualam L, Pallansch M, Wassilak S, Asghar H, Roesel S, Grabovac V, Rey-Benito G, Barnor J, Theo A, Swan J, Iakovenko M, Baig N, Gurung S, Pandel E, Zaffran M. Moffett DB, et al. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1330-1333. doi: 10.15585/mmwr.mm6937a7. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32941411 Free PMC article.
  • Genetic-Code-Expansion Strategies for Vaccine Development.
    Fok JA, Mayer C. Fok JA, et al. Chembiochem. 2020 Dec 1;21(23):3291-3300. doi: 10.1002/cbic.202000343. Epub 2020 Jul 30. Chembiochem. 2020. PMID: 32608153 Free PMC article. Review.

References

    1. Greene SA, Ahmed J, Datta SD, et al. Progress toward polio eradication—worldwide, January 2017–March 2019. MMWR Morb Mortal Wkly Rep 2019;68:458–62. 10.15585/mmwr.mm6820a3 - DOI - PMC - PubMed
    1. Previsani N, Tangermann RH, Tallis G, Jafari HS. World Health Organization guidelines for containment of poliovirus following type-specific polio eradication—worldwide, 2015. MMWR Morb Mortal Wkly Rep 2015;64:913–7. 10.15585/mmwr.mm6433a5 - DOI - PubMed
    1. Fournier-Caruana J, Previsani N, Singh H, et al. Progress toward poliovirus containment implementation—worldwide, 2017–2018. MMWR Morb Mortal Wkly Rep 2018;67:992–5. 10.15585/mmwr.mm6735a5 - DOI - PMC - PubMed
    1. Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet 2019;394:148–58. 10.1016/S0140-6736(19)31279-6 - DOI - PMC - PubMed
    1. World Health Organization. WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use—GAPIII. Geneva, Switzerland: World Health Organization; 2015. http://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf

MeSH terms